UniProt Q92793
CREB-binding protein (Q92793)
CREB-binding protein (UniProt Q92793), EC 2.3.1.-, 2.3.1.48: 226 experimental structures and 1 predicted model on GenesisL1, 82 ligands bound, 163 pockets. Binding sites, druggability and experiment against prediction (TM-score)…
- UniProt
- Q92793
- Protein
- CREB-binding protein
- EC
- 2.3.1.-, 2.3.1.48
- Experimental structures
- 226
- Predicted models
- 1
- Ligands
- 82
- Pockets
- 163 · 25 records with a druggable one
Structures
227 records of Q92793 in the MolNFT archive: 226 experimental, 1 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1JSP | NMR Structure of CBP Bromodomain in complex with p53 peptide | solution nmr | B | — | — |
| 1JSP | NMR structure of cbp bromodomain in complex with P53 peptide | solution nmr | B | — | — |
| 1LIQ | Non-native Solution Structure of a fragment of the CH1 domain of CBP | solution nmr | A | — | — |
| 1LIQ | Non-native solution structure of a fragment of the CH1 domain of cbp | solution nmr | A | — | — |
| 1WO3 | Solution structure of Minimal Mutant 1 (MM1): Multiple alanine mutant of non-native CHANCE domain | solution nmr | A | — | — |
| 1WO3 | Solution structure of minimal mutant 1 (MM1): multiple alanine mutant of non-native chance domain | solution nmr | A | — | — |
| 1WO4 | Solution structure of Minimal Mutant 2 (MM2): Multiple alanine mutant of non-native CHANCE domain | solution nmr | A | — | — |
| 1WO4 | Solution structure of minimal mutant 2 (MM2): multiple alanine mutant of non-native chance domain | solution nmr | A | — | — |
| 1WO5 | Solution structure of Designed Functional Finger 2 (DFF2): Designed mutant based on non-native… | solution nmr | A | — | — |
| 1WO5 | Solution structure of designed functional finger 2 (DFF2): designed mutant based on non-native… | solution nmr | A | — | — |
| 1WO6 | Solution structure of Designed Functional Finger 5 (DFF5): Designed mutant based on non-native… | solution nmr | A | — | — |
| 1WO6 | Solution structure of designed functional finger 5 (DFF5): designed mutant based on non-native… | solution nmr | A | — | — |
| 1WO7 | Solution structure of Designed Functional Finger 7 (DFF7): Designed mutant based on non-native… | solution nmr | A | — | — |
| 1WO7 | Solution structure of designed functional finger 7 (DFF7): designed mutant based on non-native… | solution nmr | A | — | — |
| 1ZOQ | IRF3-CBP complex | x-ray diffraction | C, D | — | — |
| 1ZOQ | IRF3-cbp complex | x-ray diffraction | C, D | — | — |
| 2D82 | Target Structure-Based Discovery of Small Molecules that Block Human p53 and CREB Binding Protein… | solution nmr | A | — | — |
| 2D82 | Target structure-based discovery of small molecules that block human P53 and creb binding protein… | solution nmr | A | — | — |
| 2KJE | NMR structure of CBP TAZ2 and adenoviral E1A complex | solution nmr | A | — | — |
| 2KJE | NMR structure of cbp TAZ2 and adenoviral E1A complex | solution nmr | A | — | — |
| 2KWF | The structure of E-protein activation domain 1 bound to the KIX domain of CBP/p300 elucidates… | solution nmr | A | — | — |
| 2KWF | The structure of E-protein activation domain 1 bound to the kix domain of CBP/P300 elucidates… | solution nmr | A | — | — |
| 2L84 | Solution NMR structures of CBP bromodomain with small molecule j28 | solution nmr | A | — | — |
| 2L84 | Solution NMR structures of cbp bromodomain with small molecule J28 | solution nmr | A | — | — |
| 2L85 | Solution NMR structures of CBP bromodomain with small molecule of HBS | solution nmr | A | — | — |
| 2L85 | Solution NMR structures of cbp bromodomain with small molecule of hbs | solution nmr | A | — | — |
| 2LXS | Allosteric communication in the KIX domain proceeds through dynamic re-packing of the hydrophobic… | solution nmr | A | — | — |
| 2LXS | Allosteric communication in the kix domain proceeds through dynamic re-packing of the hydrophobic… | solution nmr | A | — | — |
| 2LXT | Allosteric communication in the KIX domain proceeds through dynamic re-packing of the hydrophobic… | solution nmr | A | — | — |
| 2LXT | Allosteric communication in the kix domain proceeds through dynamic re-packing of the hydrophobic… | solution nmr | A | — | — |
| 2N1A | Docked structure between SUMO1 and ZZ-domain from CBP | solution nmr | B | — | — |
| 2N1A | Docked structure between SUMO1 and zz-domain from cbp | solution nmr | B | — | — |
| 2RNY | Complex Structures of CBP Bromodomain with H4 ack20 Peptide | solution nmr | A | — | — |
| 2RNY | Complex structures of cbp bromodomain with H4 ACK20 peptide | solution nmr | A | — | — |
| 3DWY | Crystal Structure of the Bromodomain of Human CREBBP | x-ray diffraction | A, B | — | — |
| 3DWY | Crystal structure of the bromodomain of human crebbp | x-ray diffraction | A, B | — | — |
| 3P1C | Crystal structure of the bromodomain of human CREBBP in complex with acetylated lysine | x-ray diffraction | A, B | — | — |
| 3P1C | Crystal structure of the bromodomain of human crebbp in complex with acetylated lysine | x-ray diffraction | A, B | — | — |
| 3P1D | Crystal structure of the bromodomain of human CREBBP in complex with N-Methyl-2-pyrrolidone (NMP) | x-ray diffraction | A, B | — | — |
| 3P1D | Crystal structure of the bromodomain of human crebbp in complex with N-methyl-2-pyrrolidone (nmp) | x-ray diffraction | A, B | — | — |
| 3P1E | Crystal structure of the bromodomain of human CREBBP in complex with dimethyl sulfoxide (DMSO) | x-ray diffraction | A, B | — | — |
| 3P1E | Crystal structure of the bromodomain of human crebbp in complex with dimethyl sulfoxide (dmso) | x-ray diffraction | A, B | — | — |
| 3P1F | Crystal structure of the bromodomain of human CREBBP in complex with a hydroquinazolin ligand | x-ray diffraction | A, B | — | — |
| 3P1F | Crystal structure of the bromodomain of human crebbp in complex with a hydroquinazolin ligand | x-ray diffraction | A, B | — | — |
| 3SVH | Crystal Structure of the bromdomain of human CREBBP in complex with a 3,5-dimethylisoxazol ligand | x-ray diffraction | A, B | — | — |
| 3SVH | Crystal structure of the bromdomain of human crebbp in complex with a 3,5-dimethylisoxazol ligand | x-ray diffraction | A, B | — | — |
| 4A9K | BROMODOMAIN OF HUMAN CREBBP WITH N-(4-hydroxyphenyl)acetamide | x-ray diffraction | A, B | — | — |
| 4A9K | Bromodomain of human crebbp with N-(4-HYDROXYPHENYL)ACETAMIDE | x-ray diffraction | A, B | — | — |
| 4N3W | Crystal Structure of the Bromodomain-PHD Finger Module of Human Transcriptional Co-Activator CBP in… | x-ray diffraction | A | — | — |
| 4N3W | Crystal structure of the bromodomain-phd finger module of human transcriptional co-activator cbp in… | x-ray diffraction | A | — | — |
| 4N4F | Crystal Structure of the Bromodomain-PHD Finger Module of Human Transcriptional Co-Activator CBP in… | x-ray diffraction | A | — | — |
| 4N4F | Crystal structure of the bromodomain-phd finger module of human transcriptional co-activator cbp in… | x-ray diffraction | A | — | — |
| 4NR4 | Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole… | x-ray diffraction | A, B | — | — |
| 4NR4 | Crystal structure of the bromodomain of human crebbp in complex with an isoxazolyl-benzimidazole… | x-ray diffraction | A, B | — | — |
| 4NR5 | Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole… | x-ray diffraction | A | — | — |
| 4NR5 | Crystal structure of the bromodomain of human crebbp in complex with an isoxazolyl-benzimidazole… | x-ray diffraction | A | — | — |
| 4NR6 | Crystal structure of the bromodomain of human CREBBP in complex with an oxazepin ligand | x-ray diffraction | A | — | — |
| 4NR6 | Crystal structure of the bromodomain of human crebbp in complex with an oxazepin ligand | x-ray diffraction | A | — | — |
| 4NR7 | Crystal structure of the bromodomain of human CREBBP in complex with an isoxazolyl-benzimidazole… | x-ray diffraction | A | — | — |
| 4NR7 | Crystal structure of the bromodomain of human crebbp in complex with an isoxazolyl-benzimidazole… | x-ray diffraction | A | — | — |
167 records more on the page itself.
Ligands
- ZN · Zinc ion · in 6 records
- SO4 · Sulfate ion · in 5 records
- NA · Sodium ion · in 4 records
- OSQ · (3~{R})-~{N}-[3-(3,4-dihydro-2~{H}-quinolin-1-yl)-2,2-bis(fluoranyl)propyl]-3-methyl-2-oxidanylidene-3,4-dihydro-1~{H}-quinoxaline-5-carboxamide · in 4 records
- CL · Chloride ion · in 3 records
- NO3 · Nitrate ion · in 3 records
- PO4 · Phosphate ion · in 3 records
- 0BC · ~{N}-(5-ethanoyl-2-ethoxy-phenyl)-3-(2~{H}-1,2,3,4-tetrazol-5-yl)-5-(1,3-thiazol-4-yl)benzamide · in 2 records
- 2LL · 5-(3,5-dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl) ethyl]-2-(2-phenylethyl)-1H-benzimidazole · in 2 records
- 4I8 · methyl 2-oxidanylidene-3~{H}-1,3-benzoxazole-6-carboxylate · in 2 records
- 6XB · 1-(3-phenylazanyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethanone · in 2 records
- 6XG · 3-[[1-(cyclopropylmethyl)-5-ethanoyl-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-3-yl]amino]-~{N}-propan-2-yl-benzamide · in 2 records
- 6XH · 1-[3-[[2-fluoranyl-4-(1-methylpyrazol-4-yl) phenyl]amino]-1-[(3~{S})-oxolan-3-yl]-6,7-dihydro-4~{H}-pyrazolo[4,3-c]pyridin-5-yl]ethanone · in 2 records
- 71X · ~{N}-[(1~{R},2~{R})-7-chloranyl-2-oxidanyl-1,2,3,4-tetrahydronaphthalen-1-yl]-4-ethanoyl-3-ethyl-5-methyl-1~{H}-pyrrole-2-carboxamide · in 2 records
- 7MX · ethyl 4-chloranyl-1-methyl-6-oxidanylidene-pyridine-3-carboxylate · in 2 records
- 7OW · 1,3-dimethyl-5-[2-(oxan-4-yl)-3-[2-(trifluoromethyloxy)ethyl]benzimidazol-5-yl]pyridin-2-one · in 2 records
- 8Q6 · dimethyl 5-[(5-ethanoyl-2-ethoxy-phenyl)amino]benzene-1,3-dicarboxylate · in 2 records
- 92E · ~{N}-[3-acetamido-5-[(5-ethanoyl-2-ethoxy-phenyl) carbamoyl]phenyl]furan-2-carboxamide · in 2 records
- 96N · 4-ethanoyl-3-ethyl-5-methyl-~{N}-(naphthalen-1-ylmethyl)-1~{H}-pyrrole-2-carboxamide · in 2 records
- 99E · ~{N}-[[2,8-bis(oxidanyl)naphthalen-1-yl]methyl]-4-ethanoyl-3-ethyl-5-methyl-1~{H}-pyrrole-2-carboxamide · in 2 records
- 9U4 · 3-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-N-methyl-1-(oxan-4-yl)-1,4, 6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridine-5-carboxamide · in 2 records
- 9U7 · 1-{3-[6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-1-[(3S)-oxolan-3-yl]-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one · in 2 records
- 9UD · 1-{3-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one · in 2 records
- AY2 · ~{N}-[3-(5-ethanoyl-2-ethoxy-phenyl)-5-(1-methylpyrazol-3-yl)phenyl]furan-2-carboxamide · in 2 records
- BKJ · 1-{3-[3-(1-methyl-1H-pyrazol-4-yl)isoquinolin-8-yl]-1-(oxan-4-yl)-1,4,6,7-tetrahydro-5H-pyrazolo[4,3-c]pyridin-5-yl}ethan-1-one · in 2 records
- C2Y · methyl 1H-indole-3-carboxylate · in 2 records
- C3J · 5-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-N-methyl-1H-indole-3-carboxamide · in 2 records
- C3V · 5-[7-(difluoromethyl)-6-(1-methyl-1H-pyrazol-4-yl)-3,4-dihydroquinolin-1(2H)-yl]-3-methyl-1,3-benzothiazol-2(3H)-one · in 2 records
- E3B · 1-[3-[3-[3,3-bis(fluoranyl)piperidin-1-yl]phenyl]-4-ethoxy-phenyl]ethanone · in 2 records
- E3H · ~{N}-[3-(5-ethanoyl-2-ethoxy-phenyl)-5-(2-ethyl-5-methyl-3-oxidanylidene-1,2-oxazol-4-yl)phenyl]furan-2-carboxamide · in 2 records
Experiment against prediction
- 5MPK chain B against the predicted model Q92793: TM-score 0.99, RMSD 0.33 Å
- 5MPK chain B against the predicted model Q92793: TM-score 0.99, RMSD 0.33 Å
- 5W0E chain A against the predicted model Q92793: TM-score 0.99, RMSD 0.35 Å
- 5W0E chain A against the predicted model Q92793: TM-score 0.99, RMSD 0.35 Å
- 5W0L chain B against the predicted model Q92793: TM-score 0.99, RMSD 0.35 Å
- 5W0L chain B against the predicted model Q92793: TM-score 0.99, RMSD 0.35 Å
- 4A9K chain B against the predicted model Q92793: TM-score 0.99, RMSD 0.35 Å
- 4A9K chain B against the predicted model Q92793: TM-score 0.99, RMSD 0.35 Å
- 4NYV chain D against the predicted model Q92793: TM-score 0.99, RMSD 0.35 Å
- 4NYV chain D against the predicted model Q92793: TM-score 0.99, RMSD 0.35 Å
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.